HB 1745 — Improving diversity in clinical trials.

H-1358.1H-0972.1 SUBSTITUTE HOUSE BILL 1745 State of Washington 68th Legislature 2023 Regular Session By House Health Care & Wellness (originally sponsored by Representatives Thai, Duerr, Doglio, Ormsby, and Macri)Macri READRead FIRSTfirst TIMEtime 02/17/23.02/03/23.

Referred to Committee on Health Care & Wellness.

1 SHBHB 1745 commercialization and includes the costs of recruiting scientists and establishing and equipping research facilities.

2 SHBHB 1745 included in research and clinical trials represented by race, sex, sexual orientation, socioeconomic status, age, and geographic location.

(k) the ability to provide electronic consentconsent; when not prohibited by other granting entities or federal regulations;

3 SHBHB 1745 outreach and engagement to increase participation of underrepresented communities in clinical trialstrials. of drugs and medical devices.

4 SHBHB 1745 designated institutional review board for the department of social and health services, the department of health, the department of labor and industries, and other state agencies.

(3) The ability to provide electronic consentconsent; when not prohibited by the granting entity or federal regulation;

and (4) Any other evidence of outreach and engagement to increase participation of underrepresented communities in clinical trialstrials. of drugs or medical devices.

Any state entity that receives funding from the national institutes of health to conduct clinical trials of drugs or medical devices shall adopt a policy concerning the identification and recruitment of persons who are members of underrepresented demographic groups to participate in clinical trialstrials. of drugs or medical devices.

(3) Provide electronic consentconsent; when not prohibited by the granting entity or federal regulation;

and (4) Provide other strategies of outreach and engagement to increase participation of underrepresented communities in clinical trialstrials. of drugs or medical devices.

(1) If at any time the University of Washington receives funding from the national institutes of health to conduct clinical trials of drugs or medical devices, the University of Washington shall adopt a policy concerning the identification and recruitment of persons who p.are members of underrepresented demographic groups to participate in clinical trials.

5 SHB 1745 are members of underrepresented demographic groups to participate in clinical trials of drugs or medical devices.

(b)p. Provide culturally specific recruitment materials alongside general enrollment materials;

(c)5 ProvideHB electronic1745 consent(b) whenProvide notculturally prohibitedspecific byrecruitment thematerials grantingalongside entitygeneral orenrollment federalmaterials; regulation;

and(c) (d) Provide otherelectronic strategiesconsent; of outreach and engagement to increase participation of underrepresented communities in clinical trials of drugs or medical devices.

and (d) Provide other strategies of outreach and engagement to increase participation of underrepresented communities in clinical trials.

(1) If at any time Washington State University receives funding from the national institutes of health to conduct clinical trials of drugs or medical devices, Washington State University shall adopt a policy concerning the identification and recruitment of persons who are members of underrepresented demographic groups to participate in clinical trialstrials. of drugs or medical devices.

(c) Provide electronic consentconsent; when not prohibited by the granting entity or federal regulation;

and (d) Provide other strategies of outreach and engagement to increase participation of underrepresented communities in clinical trialstrials. of drugs or medical devices.

(2) "Underrepresented community" or "underrepresented demographic group" means a community or demographic group that is more likely to be historically marginalized and less likely to be included in p.research and clinical trials represented by race, sex, sexual orientation, socioeconomic status, age, and geographic location.

6 SHB 1745 research and clinical trials represented by race, sex, sexual orientation, socioeconomic status, age, and geographic location.

(1) Any hospital that receives funding from the national institutes of health to conduct clinical trials of drugs or medical devices shall adopt a policy concerning the identification and recruitmentp. of persons who are members of underrepresented demographic groups to participate in clinical trials of drugs or medical devices.

6 HB 1745 recruitment of persons who are members of underrepresented demographic groups to participate in clinical trials.

(c) Provide electronic consentconsent; when not prohibited by the granting entity or federal regulation;

and (d) Provide other strategies of outreach and engagement to increase participation of underrepresented communities in clinical trialstrials. of drugs or medical devices.

7 SHBHB 1745